Clinical Trial

Open-Label Extension and Safety Study of Talazoparib

Study Description

Open-Label Extension and Safety Study of Talazoparib

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Talazoparib

Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol

Additional Information

Official Study Title

A SINGLE-ARM, OPEN-LABEL, MULTICENTER, EXTENDED TREATMENT, SAFETY STUDY IN PATIENTS TREATED WITH TALAZOPARIB

Clinical Trial ID

NCT02921919

ParticipAid ID

9aA7ld